Lilly MDD H9P-MC-LNBR
A Randomized Placebo-Controlled, Double-Blind Study of (study drug)Flexible-Dose 12 to 18 mg Once Daily as Adjunctive Treatment for Patients with Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
| Protocol | H9P-MC-LNBR |
|---|
| Identifier | H9P-MC-LNBR |
|---|
| UID | 81a77603-0a50-4324-8cb5-e84d98bc3a3a |
|---|
| Status | Done - Archived |
|---|
| Phase | 3 |
|---|
| Category | Major Depressive Disorder / Adult |
|---|
| Launch Year | 2011 |
|---|
| NCT Number | - |
|---|
| Created | 2010-12-10 13:08 |
|---|
| Last Updated | 2010-12-10 13:08 |
|---|
Description
Key Elements:
• Study drug LY2216684 is being studies as adjunct therapy in patients who are partially responding to SSRIs and may still be experiencing sleep disturbance, fatigues, loss of interest, and difficulty concentrating.
• Patients will continue on their current SSRI treatment throughout the study.
• Pharmacy card will be provided at Visit 2/Randomization to help pay for their current SSRI treatment throughout the trial.
• 13 Weekly visits (including Safer Interview)
• $45 per visit
• Patients will meet with Dr. Martinez or Dr. Mohaupt at every visit.
Comment
No comment.
